Samsung BioLogics Co Ltd 207940
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 207940 is a good fit for your portfolio.
News
-
Samsung Biologics Reports First Quarter 2024 Financial Results
-
Samsung Invests in BrickBio to Develop Advanced Molecules and Therapies Using Protein Engineering Technology for Antibody-Drug Conjugates (ADC)
-
Samsung Biologics awarded Leadership status by CDP for climate action efforts
-
Samsung Biologics partners with LegoChem Biosciences for ADC development and manufacturing
-
Rapid Micro Biosystems Shares Rise After Samsung Biologics Partnership
Trading Information
- Previous Close Price
- KRW 775,000.00
- Day Range
- KRW 775,000.00–787,000.00
- 52-Week Range
- KRW 668,000.00–880,000.00
- Bid/Ask
- KRW 781,000.00 / KRW 782,000.00
- Market Cap
- KRW 55.59 Tril
- Volume/Avg
- 60,733 / 65,543
Key Statistics
- Price/Earnings (Normalized)
- 64.62
- Price/Sales
- 15.05
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Samsung BioLogics Co Ltd engaged in development and manufacturing of bio-healthcare products.The Company works namely in Process Development, cGMP Manufacturing, Aseptic Fill and Finish.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Growth
- Total Number of Employees
- 4,519
- Website
- https://www.samsungbiologics.com
Comparables
Valuation
|
Metric
|
207940
|
085660
|
107590
|
|---|---|---|---|
Price/Earnings (Normalized) | 64.62 | — | 12.09 |
Price/Book Value | 5.65 | 3.43 | 0.78 |
Price/Sales | 15.05 | 1.07 | 0.41 |
Price/Cash Flow | 40.65 | 36.41 | 9.12 |
Price/Earnings
207940
085660
107590
Financial Strength
|
Metric
|
207940
|
085660
|
107590
|
|---|---|---|---|
Quick Ratio | 0.67 | 0.73 | 0.65 |
Current Ratio | 1.33 | 0.83 | 1.23 |
Interest Coverage | 13.55 | 0.67 | 4.42 |
Quick Ratio
207940
085660
107590
Profitability
|
Metric
|
207940
|
085660
|
107590
|
|---|---|---|---|
Return on Assets (Normalized) | 5.39% | −0.51% | 3.42% |
Return on Equity (Normalized) | 9.29% | −2.90% | 7.38% |
Return on Invested Capital (Normalized) | 7.37% | 0.33% | 5.39% |
Return on Assets
207940
085660
107590
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rrwbbkysp | Fkk | $578.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mnjxskyvl | Yxtssyy | $101.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rywvyjh | Mydkk | $98.1 Bil | |
MRNA
| Moderna Inc | Xsgcxvs | Qwmcn | $42.2 Bil | |
ARGX
| argenx SE ADR | Syczzxfnf | Tcgx | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Gkckrrwf | Pgqf | $21.4 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xfzvjgqh | Blvrqqb | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wmybkgphx | Mcqpvp | $15.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xydrcdmfnk | Ngdjby | $12.5 Bil | |
INCY
| Incyte Corp | Kmmwrbn | Mskxzb | $11.7 Bil |